Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas

Yoshinao Oda, Yasunori Oda, Shinichi Aishima, Katsuya Morimatsu, Akifumi Hayashi, Koji Shindo, Minoru Fujino, yusuke mizuuchi, Masami Hattori, Masao Tanaka

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Intraductal papillary mucinous neoplasms (IPMNs) and pancreatic intraepithelial neoplasia (PanINs) are important premalignant lesions of pancreatic cancer. Ezrin is a member of the ezrin, radixin, and moesin protein family and acts as a cross-linker between the plasma membrane and the actin cytoskeleton. We investigated the roles of ezrin during carcinogenesis in IPMN and invasive ductal carcinoma and examined whether ezrin was a prognostic factor. We examined ezrin and phosphorylated ezrin (p-ezrin) expression in 131 IPMNs, 47 PanINs, and 59 invasive ductal carcinomas by immunohistochemical staining. Ezrin and p-ezrin (tyr354) expressions were significantly higher in IPMN with an associated invasive carcinoma, compared with those in IPMN with high-grade dysplasia (P =.03 and P =.0007, respectively). In all grades of PanINs, ezrin and p-ezrin (tyr353) were highly expressed. In patients with invasive ductal carcinoma, the presence of PanIN-2 or PanIN-3 was significantly correlated with positive ezrin and p-ezrin (tyr353) expression of the invasive ductal carcinoma component (P =.01 and P =.0004). The negative p-ezrin (tyr353) expression group of invasive ductal carcinoma showed a significantly worse prognosis than did the positive p-ezrin (tyr353) expression group by survival analysis (P =.04) and was a statistically significant adverse prognostic factor by both univariate and multivariate analyses (P =.048 and P =.015). Ezrin phosphorylation sites differ between the developments of IPMN and PanIN. Although p-ezrin (tyr354) expression in IPMNs is associated with tumor invasion, p-ezrin (tyr353) expression in invasive ductal carcinoma plays an important role not in tumor invasion and metastasis but in the early development of PanINs.

Original languageEnglish
Pages (from-to)1487-1498
Number of pages12
JournalHuman Pathology
Volume44
Issue number8
DOIs
Publication statusPublished - Aug 1 2013

Fingerprint

Pancreatic Ductal Carcinoma
Ductal Carcinoma
Neoplasms
Pancreatic Neoplasms
ezrin

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas. / Oda, Yoshinao; Oda, Yasunori; Aishima, Shinichi; Morimatsu, Katsuya; Hayashi, Akifumi; Shindo, Koji; Fujino, Minoru; mizuuchi, yusuke; Hattori, Masami; Tanaka, Masao.

In: Human Pathology, Vol. 44, No. 8, 01.08.2013, p. 1487-1498.

Research output: Contribution to journalArticle

Oda, Yoshinao ; Oda, Yasunori ; Aishima, Shinichi ; Morimatsu, Katsuya ; Hayashi, Akifumi ; Shindo, Koji ; Fujino, Minoru ; mizuuchi, yusuke ; Hattori, Masami ; Tanaka, Masao. / Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas. In: Human Pathology. 2013 ; Vol. 44, No. 8. pp. 1487-1498.
@article{082d7729e74445558bdde660629d31c6,
title = "Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas",
abstract = "Intraductal papillary mucinous neoplasms (IPMNs) and pancreatic intraepithelial neoplasia (PanINs) are important premalignant lesions of pancreatic cancer. Ezrin is a member of the ezrin, radixin, and moesin protein family and acts as a cross-linker between the plasma membrane and the actin cytoskeleton. We investigated the roles of ezrin during carcinogenesis in IPMN and invasive ductal carcinoma and examined whether ezrin was a prognostic factor. We examined ezrin and phosphorylated ezrin (p-ezrin) expression in 131 IPMNs, 47 PanINs, and 59 invasive ductal carcinomas by immunohistochemical staining. Ezrin and p-ezrin (tyr354) expressions were significantly higher in IPMN with an associated invasive carcinoma, compared with those in IPMN with high-grade dysplasia (P =.03 and P =.0007, respectively). In all grades of PanINs, ezrin and p-ezrin (tyr353) were highly expressed. In patients with invasive ductal carcinoma, the presence of PanIN-2 or PanIN-3 was significantly correlated with positive ezrin and p-ezrin (tyr353) expression of the invasive ductal carcinoma component (P =.01 and P =.0004). The negative p-ezrin (tyr353) expression group of invasive ductal carcinoma showed a significantly worse prognosis than did the positive p-ezrin (tyr353) expression group by survival analysis (P =.04) and was a statistically significant adverse prognostic factor by both univariate and multivariate analyses (P =.048 and P =.015). Ezrin phosphorylation sites differ between the developments of IPMN and PanIN. Although p-ezrin (tyr354) expression in IPMNs is associated with tumor invasion, p-ezrin (tyr353) expression in invasive ductal carcinoma plays an important role not in tumor invasion and metastasis but in the early development of PanINs.",
author = "Yoshinao Oda and Yasunori Oda and Shinichi Aishima and Katsuya Morimatsu and Akifumi Hayashi and Koji Shindo and Minoru Fujino and yusuke mizuuchi and Masami Hattori and Masao Tanaka",
year = "2013",
month = "8",
day = "1",
doi = "10.1016/j.humpath.2012.12.001",
language = "English",
volume = "44",
pages = "1487--1498",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas

AU - Oda, Yoshinao

AU - Oda, Yasunori

AU - Aishima, Shinichi

AU - Morimatsu, Katsuya

AU - Hayashi, Akifumi

AU - Shindo, Koji

AU - Fujino, Minoru

AU - mizuuchi, yusuke

AU - Hattori, Masami

AU - Tanaka, Masao

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Intraductal papillary mucinous neoplasms (IPMNs) and pancreatic intraepithelial neoplasia (PanINs) are important premalignant lesions of pancreatic cancer. Ezrin is a member of the ezrin, radixin, and moesin protein family and acts as a cross-linker between the plasma membrane and the actin cytoskeleton. We investigated the roles of ezrin during carcinogenesis in IPMN and invasive ductal carcinoma and examined whether ezrin was a prognostic factor. We examined ezrin and phosphorylated ezrin (p-ezrin) expression in 131 IPMNs, 47 PanINs, and 59 invasive ductal carcinomas by immunohistochemical staining. Ezrin and p-ezrin (tyr354) expressions were significantly higher in IPMN with an associated invasive carcinoma, compared with those in IPMN with high-grade dysplasia (P =.03 and P =.0007, respectively). In all grades of PanINs, ezrin and p-ezrin (tyr353) were highly expressed. In patients with invasive ductal carcinoma, the presence of PanIN-2 or PanIN-3 was significantly correlated with positive ezrin and p-ezrin (tyr353) expression of the invasive ductal carcinoma component (P =.01 and P =.0004). The negative p-ezrin (tyr353) expression group of invasive ductal carcinoma showed a significantly worse prognosis than did the positive p-ezrin (tyr353) expression group by survival analysis (P =.04) and was a statistically significant adverse prognostic factor by both univariate and multivariate analyses (P =.048 and P =.015). Ezrin phosphorylation sites differ between the developments of IPMN and PanIN. Although p-ezrin (tyr354) expression in IPMNs is associated with tumor invasion, p-ezrin (tyr353) expression in invasive ductal carcinoma plays an important role not in tumor invasion and metastasis but in the early development of PanINs.

AB - Intraductal papillary mucinous neoplasms (IPMNs) and pancreatic intraepithelial neoplasia (PanINs) are important premalignant lesions of pancreatic cancer. Ezrin is a member of the ezrin, radixin, and moesin protein family and acts as a cross-linker between the plasma membrane and the actin cytoskeleton. We investigated the roles of ezrin during carcinogenesis in IPMN and invasive ductal carcinoma and examined whether ezrin was a prognostic factor. We examined ezrin and phosphorylated ezrin (p-ezrin) expression in 131 IPMNs, 47 PanINs, and 59 invasive ductal carcinomas by immunohistochemical staining. Ezrin and p-ezrin (tyr354) expressions were significantly higher in IPMN with an associated invasive carcinoma, compared with those in IPMN with high-grade dysplasia (P =.03 and P =.0007, respectively). In all grades of PanINs, ezrin and p-ezrin (tyr353) were highly expressed. In patients with invasive ductal carcinoma, the presence of PanIN-2 or PanIN-3 was significantly correlated with positive ezrin and p-ezrin (tyr353) expression of the invasive ductal carcinoma component (P =.01 and P =.0004). The negative p-ezrin (tyr353) expression group of invasive ductal carcinoma showed a significantly worse prognosis than did the positive p-ezrin (tyr353) expression group by survival analysis (P =.04) and was a statistically significant adverse prognostic factor by both univariate and multivariate analyses (P =.048 and P =.015). Ezrin phosphorylation sites differ between the developments of IPMN and PanIN. Although p-ezrin (tyr354) expression in IPMNs is associated with tumor invasion, p-ezrin (tyr353) expression in invasive ductal carcinoma plays an important role not in tumor invasion and metastasis but in the early development of PanINs.

UR - http://www.scopus.com/inward/record.url?scp=84880333639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880333639&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2012.12.001

DO - 10.1016/j.humpath.2012.12.001

M3 - Article

C2 - 23465281

AN - SCOPUS:84880333639

VL - 44

SP - 1487

EP - 1498

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 8

ER -